Abstract
The addition of long-acting muscarinic antagonists in the therapy of severe uncontrolled asthma improves the control of the disease. The new possibility for the treatment is the single-inhaler triple therapy (inhaled corticosteroids with the dual combination of bronchodilatators) with extrafine formulation which reaches the small airways.
Efficacy in the treatment, the safety and the easier manipulation with the inhaler improves the quality of the life and makes stronger the patient'scompliance to the therapy